Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 24% Improvement Relative Risk c19hcq.org Synolaki et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 312 patients in Greece Lower mortality with HCQ (not stat. sig., p=0.27) Synolaki et al., medRxiv, doi:10.1101/2020.09.05.20184655 Favors HCQ Favors control
The Activin/Follistatin-axis is severely deregulated in COVID-19 and independently associated with in-hospital mortality
Synolaki et al., medRxiv, doi:10.1101/2020.09.05.20184655 (Preprint)
Synolaki et al., The Activin/Follistatin-axis is severely deregulated in COVID-19 and independently associated with in-hospital.., medRxiv, doi:10.1101/2020.09.05.20184655 (Preprint)
Sep 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 117 patients, 58 HCQ showing lower mortality for HCQ patients.
Version 1 of this paper stated: "HCQ, AZ, [and ...] were found to be independently associated with survival when treatment commenced at FACTCLINYCoD scores <3".
Although the 24% lower mortality is not statistically significant, it is consistent with the significant 22% lower mortality [18‑27%] from meta analysis of the 232 mortality results to date.
risk of death, 23.6% lower, RR 0.76, p = 0.27, treatment 21 of 98 (21.4%), control 60 of 214 (28.0%), NNT 15.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Synolaki et al., 5 Sep 2020, retrospective, Greece, preprint, 20 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.09.05.20184655; this version posted October 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Running head: Activin/Follistatin-axis in COVID-19 The Activin/Follistatin-axis is severely deregulated in COVID-19 and independently associated with in-hospital mortality Evgenia Synolaki1, Vasileios Papadopoulos2*, Georgios Divolis1*, Olga Tsahouridou3, Efstratios Gavriilidis2, Georgia Loli3, Ariana Gavriil1, Christina Tsigalou4, Nikolaos R. Tziolos5, Eleni Sertaridou6, Bhanu Kalra7, Ajay Kumar7, Petros Rafailidis8, Arja Pasternack9, Dimitrios T. Boumpas5, Georgios Germanidis3, Olli Ritvos9, Simeon Metallidis3, Panagiotis Skendros2,10,# and Paschalis Sideras1,# 1 Biomedical Research Foundation Academy of Athens, Center for Clinical, Experimental Surgery & Translational Research, Athens, Greece; 2First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece; 3First Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece; 4 Laboratory of Microbiology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece; 5Fourth Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece; 6Intensive Care Unit, University Hospital of Alexandroupolis, Alexandroupolis, Greece; 7AnshLabs, Webster, Texas, USA; 8Second Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece; 9 Department of Physiology, Faculty of Medicine, University of Helsinki, Helsinki, Finland; 10Laboratory of Molecular Hematology, Democritus University of Thrace, Alexandroupolis, Greece; 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.09.05.20184655; this version posted October 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . * These authors contributed equally to the study. # These authors supervised equally the study. Corresponding author: Dr. Paschalis Sideras; Biomedical Research Foundation Academy of Athens, Center for Clinical, Experimental Surgery & Translational Research, Athens, Greece; tel: +302106597183; e-mail: sideras@bioacademy.gr 2 medRxiv preprint doi: https://doi.org/10.1101/2020.09.05.20184655; this version posted October 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Potential conflicts of interest: Authors BK and AK are employees of Ansh Labs, which is the manufacturer of the ELISA kits used in this study. The rest of the authors declare no conflict of interest. Funding Support: This work was supported by grants from the General..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit